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Introduction 
There are two types of metabolic pathways utilized to obtain energy: anaerobic 
glycolysis and oxidative phosphorylation. In anaerobic glycolysis, the start molecule is 
glucose, and the end product is lactic acid. Oxidative phosphorylation also starts with 
glucose, but converts it into pyruvate, which then enters the tricarboxylic acid cycle, 
followed by the electron transport chain. Cancer cells prefer to use anaerobic 
glycolysis as their means of obtaining energy, even in the presence of oxygen. This 
phenomenon is known as the Warburg effect, where cancer cells go through aerobic 
glycolysis—following the anaerobic glycolysis pathway even in the presence of 
oxygen. By utilizing anaerobic glycolysis, cancer cells are able to obtain energy much 
faster as opposed to when using aerobic glycolysis, which explains a tumor’s capability 
of proliferating at a rapid pace.2 
 
Chemotherapy is one method of treating cancer, but does not guarantee curing it, for 
the treatment sometimes does not kill all the cells, which may cause the cancer to 
regress. Understanding the change in metabolism of these drug-resistant cancer cells 
provides a potential target for cancer treatment, with the possibility of curing cancer. 
The goal of this study is to simulate dormancy in the MCF-7 cell line, a form of breast 
cancer, and discover the key differences in its metabolism in comparison to the native 
wildtype cells. In this study, doxorubicin was the chemotherapy drug utilized to create 
drug-resistant MCF-7 cell lines, which prevents cell growth by proteolytically cleaving 
cAMP responsive element binding protein 3-like 1 (CREB3L1), a transcription factor, 
via the production of ceramide.3 
 
Cell Culturing 
Cells were grown in a T-75 flask with RPMI media containing 10% FBS and 1% 
penicillin/strep, and stored in an incubator under 37°C. Cells that were to be treated 
with drug were trypsinized and transferred to 25-cm small plates. Doxorubicin was 
dosed in concentrations of 1 µM, 2 µM, 2.5 µM, 3 µM, 4 µM, and 5 µM. Cell cultures 
were refreshed with new RPMI media whenever the media (originally orange) turned 
yellow, an indicator that the cell culture had consumed all of the nutrients in the media 
and that the culture was slowly becoming acidic. When the confluency of the small 
plates was full, meaning, when the surface of the plate was covered with cells, and 
there were no empty spaces, 1 mL of trypsin was used to loosen cells from the plate 
surface. To neutralize the trypsin, 4 mL of RPMI media was used. 1 mL of the total 
solution was then passed to a new small plate, with an additional 4 mL of RPMI media 
to continue the culture at 20% plate confluency. In T-75 flasks, dosed cultures that 
were stable in confluency for three days were scraped, collected, and frozen for future 
use for the MTT assay.  
 
 
 
 
 
 
 
 
Figure 1: A time-progressive graph of the confluency 
 of MCF-7 cells treated with 2.5 µM Doxorubicin 
 
Treated cells were considered to be drug-resistant if its cell confluency initially 
declined, but then stabilized at a lower percentage. We refer to this stage as 
“dormancy”. We discovered that doxorubicin was most effective in achieving 
dormancy with a concentration range of 2uM – 3 µM, although cells tended to 
die off approximately a week after initial treatment. Figure 1 showed the 
progress in confluency of one of the cell treatments, with 2.5 µM doxorubicin. 
During the weekends, confluency was not recorded. This cell line was used in 
the MTT assay conducted for this study. Cells were hard to maintain because it 
was difficult to predict if cells would proliferate or die. The data obtained from the 
treated cells could not explain the MCF-7 cell line’s behavior in the presence of 
doxorubicin. However, it had been noticed that if drug treatment was started at a 
high confluency, it would take much longer before the cells began to show a 
decline in cell population.  
 
 
 
 
Doxorubicin Treatments 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Morphology observations of doxorubicin-treated MCF-7 cells. 1: Wildtype MCF-7 cell line. 
2: 1 µM Doxorubicin-treated   MCF-7 cell line. 3: 2.5 µM Doxorubicin-treated MCF-7 cell line. 4: 5 µM 
Doxorubicin-treated MCF-7 cell line. 5. 10 µM Doxorubicin-treated MCF-7 cell line. 
 
Based on Figure 2, the treatments showed that doses higher than 5uM were too 
strong to create drug-resistant cancer cell lines, as all of the cells died at a 
concentration of 10 µM. However, doxorubicin doses of 1uM and 2.5uM caused the 
cells to exhibit a morphology change. As opposed to the more rounded shape of 
MCF-7 cells in wildtype form, cells treated with concentrations of either 1uM or 2.5uM 
became more elongated and thinner at the ends, while the middle of the cells 
remained round. We believe that this change in morphology is what allows MCF-7 
cells to adapt in the presence of doxorubicin, so that they have a higher chance of 
staying alive. 
 
MTT Assay 
MTT Assay was conducted to test for the toxicity and therefore viability of the cell 
lines as followed by a protocol from Waller and Provost Lab. This assay involves 
reducing 30(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (yellow MTT) 
to a purple formazon in the mitochondria of alive cells. Mitochondrial dehydrogenases 
cleave the tetrazolium ring in the mitochondria in order create purple MTT formazan 
crystals, which are insoluble without the addition of another solvent. DMSO was used 
to solubilize the formazan crystals.  
 
 
 
 
 
Table 1: Setup of the 96-well plate for the MTT assay. 
 
 
 
 
 
 
 
 
 
Figure 3: Results from the MTT assay. 
 
The setup for the MTT assay is shown in Table 1. Using a 96-well plate, 36 wells 
were used in the assay to test 2.5 µM and 5.0 µM doxorubicin-treated cells in order to 
determine whether or not the treated cells were drug resistant. Along with a control, 
each type of cell line was tested in triplicates. The three cell lines were given four 
different types of treatments: control, 2.5 µM, 5 µM, and 10 µM doxorubicin. Each well 
was aimed to have 2,500 cells/mL, and contained a volume of 200 uL. After setting up 
the well plate, cells were given one day to acclimate to the new environment before 
treating with various concentrations of doxorubicin. Once cells were incubated for 
another day, 20 mL of 5 g/mL thiazolyl blue tetrazolium bromide (MTT solution) was 
added to each well. After ten minutes of gentle shaking, each well’s absorbance was 
recorded via spectrophotometer at 600 nm.8 
It was predicted that the treated cell lines would exhibit resistance to cell dosage. 
Meaning, the 2.5 µM cell line should have shown enhanced survival in comparison 
to the other cells when treated with 2.5 µM doxorubicin. However, the data has 
shown that in all dosage treatments, the wildtype cells survived more than the 
treated cell lines. Because this assay was also performed only once, a conclusion 
cannot be made with this data. However, this experiment suggests that the treated 
cell lines, though not drug-resistant, were more weakened to the cell treatment, 
meaning the treated cell lines were more affected by the drug in comparison to 
wildtype.  
 
Discussion 
This study was conducted for ten weeks; for three of those ten weeks, there was a 
contamination problem in the cell incubator, thus compromising most cells with yeast 
growth. Due to this contamination issue and the limited amount of time to conduct 
research, it was difficult to maintain growth of MCF-7 cells, and observe the 
confluency trend of treated cells. This issue was resolved towards the last two weeks 
of research. The figures shown in this report reflect data from MCF-7 cells that were 
uncontaminated. Due to the contamination, there was a lack of several viable cell 
lines available for analysis and documentation in this report 
 
We plan to continue treating MCF-7 cells with doxorubicin in order to create drug-
resistant cells and find a more concrete dosage range of which doxorubicin can be 
used to create said cell lines, as well as confirm the findings from the MTT assay, 
which suggest the cell lines made were not resistant, only weakened. These cell 
lines will then be measured via oxygen electrode in order to further analyze the 
mitochondria activity of these cells by measuring the amount of aerobic respiration, 
and to compare them to wildtype MCF-7 cells. Future MTT assays will be done with 
cell lines that have had stable confluency for a longer period of time longer than 
three days. When it is confirmed through MTT assays and the oxygen electrode that 
drug resistant cell lines were successfully created, cells will then be analyzed by 
electron microscope in order to obtain a more accurate visual in terms of 
morphological changes in MCF-7 cells. From there, we intend to discover the same 
findings with another drug, cyclophosphamide, in order to see if different 
chemotherapy agents would require different concentrations to make MCF-7 cells 
drug resistant, as well as if similar or different morphological changes can be 
observed. 
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